Brief: Calidi Biotherapeutics Announces Pricing Of $5.2 Million Underwritten Public Offering
06/03/2026 13:34
March 6 (Reuters) - Calidi Biotherapeutics Inc CLDI.A: CALIDI BIOTHERAPEUTICS ANNOUNCES PRICING OF $5.2 MILLION UNDERWRITTEN PUBLIC OFFERING Source text: ID:nGNX2vK01b Further company coverage: CLDI.A ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Calidi Biotherapeutics
See all newsBrief: Calidi Biotherapeutics Announces Strategic Partnership With Transferai
Brief: Calidi Biotherapeutics Announces Partnership With Avance Clinical To Facilitate Australian Regulatory Approval
Brief: Calidi Biotherapeutics Announces Pricing Of $5.2 Million Underwritten Public Offering
Brief: Calidi Biotherapeutics Eliminates Chief Legal Officer Position - SEC Filing
Brief: Calidi Biotherapeutics Receives FDA Fast Track Designation For Cld-201 (Supernova), A First-In-Class Stem-Cell Loaded Viral Therapy For The Treatment Of Patients With Soft Tissue Sarcoma